OKYO Pharma Ltd

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It targets to cure and prevent the following conditions: dry eye disease, non-infectious anterior uveitis, allergic conjunctivitis, and ocular pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering. All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of ordinary shares sold in this offering to cover over-allotments, if any. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying OKYO that, for the previous 30 consecutive business days, the market value of OKYO's ordinary shares had closed below the minimum $35 million requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the "Market Value Rule").

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

OKYO Pharma Ltd (NASDAQ:OKYO) has revealed a new partnership with Tufts Medical Center to conduct an open-label clinical trial to assess the efficacy and safety of OK-101 in treating patients with neuropathic corneal pain (NCP). NCP is a distressing condition that causes chronic and severe eye discomfort, severely impacting the quality of life for those affected.

OKYO Pharma inks collaboration with Tufts Medical Center

LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce a new agreement with Tufts Medical Center to conduct a 40-patient open-label clinical trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain (“NCP”). The Investigational New Drug (“IND”) application for NCP is planned to be filed in Q4 of 2023, with study enrollment planned to commence shortly after IND allowance by the FDA.

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Operating Officer. Mr Clementi will formally take up the COO role effective September 1, 2023. Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team.

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

OKYO Pharma said patients are being dosed in a randomise portion of a phase 2 trial for its OK-101 drug to treat dry eye disease (DED). The ophthalmology-focused biopharmaceutical company said in a statement that patients are being dosed in the phase 2 trial following a two-week placebo run-in period, which is designed to minimise the placebo effect.

OKYO Pharma begins OK-101 phase 2 dosing

LONDON and NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that patients are now being dosed in the randomized portion of the phase 2, multi-center, double-masked, placebo-controlled trial of topical ocular OK-101 to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect.

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

BALTIMORE, MD / ACCESSWIRE / May 9, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on OKYO Pharma Limited (NASDAQ:OKYO), an emerging player in the fast-growing ophthalmic drugs segment. The Goldman report carries a price target.

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), an ophthalmology-focused biopharmaceutical company, will showcase two presentations on its dry eye disease (DED) treatment, OK-101, at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, California, from May 5-8. Dr Pedram Hamrah, a leading expert on corneal neuropathic pain and DED, will present both papers at the conference.

OKYO Pharma to address key conference with data on dry eye drug

LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that two presentations will be given on OK-101 at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023.

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said the first patient had been screened for the phase II trial of OK-101, a treatment for dry eye disease (DED). It aims to evaluate the drug's efficacy and safety in DED patients.

OKYO Pharma screens first patient for dry eye disease trial

LONDON and NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that the first patient has been screened for its phase 2, multi-center, randomized, double–blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease (DED).

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), an ophthalmology-focused biotech, said has activated its first clinical trial site in the United States for a phase II trial evaluating the efficacy and safety of its dry eye disease treatment, OK-101. This multi-centre, randomised, double-blinded, and placebo-controlled study is expected to accept its first patient in within two weeks.

OKYO Pharma ready to kick off dry eye trial in the US

LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease. First patient first visit is presently expected to occur within the next two weeks.

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

LONDON, UK and NEW YORK, NY / ACCESSWIRE / April 18, 2023 / Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). However, when a company is bringing a drug to trial in near-record time, it's understandable that company insiders - including the management - might feel more enthusiastic about the prospects of the drug.

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

LONDON and NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, announces that, further to its announcement on 4 April 2023, it has today posted a circular (the "Circular") to shareholders which contains further details regarding the proposed cancellation of its ordinary shares of no par value each ("Ordinary Shares") from listing on the standard segment of the Official List of the Financial Conduct Authority and trading on the main market for listed securities of London Stock Exchange plc and associated timetable, together with proposals to be put to shareholders at a general meeting of the Company to be held at the offices of Orrick, Herrington & Sutcliffe (UK) LLP at 107 Cheapside, London EC2V 6DN, United Kingdom at 12.00 midday on 3 May 2023 (the "General Meeting"), including, inter alia, to consolidate every 65 existing Ordinary Shares into one new ordinary share of no par value (thereby matching its current American Depositary Share ratio). The Circular will shortly be posted to the Company's website at: https://okyopharma.com/investors/corporate-governance/corporate-documents/

Notice of General Meeting and Publication of Circular

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), which is developing OK-101 to treat dry eye disease, has applied to cancel its listing on the standard segment on the London Stock Exchange. The company's American Depositary Shares (ADSs) traded on Nasdaq will not be unaffected by the move.

OKYO Pharma plans UK de-listing in favour of US quote

LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces that it has applied to the UK Financial Conduct Authority ("FCA") and London Stock Exchange plc ("LSE") to effect a cancellation of its ordinary shares of no par value each ("Ordinary Shares") from listing on the standard segment of the FCA's Official List and trading on the main market for listed securities of the LSE ("Main Market") ("Delisting").

Notice of Intention to Delist From The London Stock Exchange

LONDON and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 11,000 of the Company's ADSs on NASDAQ at a price of US$1.41 per ADS (which would be equivalent to the purchase of 715,000 ordinary shares of no par value ("Ordinary Shares") at a price of £0.0176 each).

OKYO Pharma Today Announces Director Acquires Shares

LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 10,000 of the Company's ADSs on NASDAQ at a price of US$1.40 per ADS (which would be equivalent to the purchase of 650,000 ordinary shares of no par value ("Ordinary Shares") at a price of £0.0175 each).

OKYO Pharma Announces PDMR Dealing

OKYO Pharma's London-listed shares soared on Friday after the biopharmaceutical company announced it has started a trial process for its dry eye disease treatment OK-101. The company's lipidated chemerin-peptide drug candidate OK-101 is designed to target a key ocular receptor controlling inflammation and ocular pain.

OKYO Pharma shares soar on news it is gearing up for dry eye disease treatment trial

Okyo Pharma (NASDAQ: OKYO ) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of OK-101. OK-101 is the company's drug candidate for the treatment of DED.

Why Is Okyo Pharma (OKYO) Stock Up 13% Today?

Inhibikase Therapeutics

Lipella Pharmaceuticals Inc

Sidus Space

Penny stocks to watch after big news this week The post Penny Stocks To Buy? 4 To Watch Now After Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy? 4 To Watch Now After Big News

OKYO Pharma said its trial evaluating the efficacy and safety of OK-101 in subjects with dry eye diseases (DED)  has been posted on the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208). OKYO added it is presently in the process of activating those clinical sites planned for the trial and preparing the clinical trial drug product OK-101 for shipment to those sites.

OKYO Pharma starts trial process for dry eye disease treatment

LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208). ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

News for OKYO Pharma Ltd Stock (OKYO)